当前位置：
X-MOL 学术
›
Lancet Respir. Med.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, phase 3 study
The Lancet Respiratory Medicine ( IF 38.7 ) Pub Date : 2024-10-29 , DOI: 10.1016/s2213-2600(24)00264-9 Hervé Léna MD, Prof Laurent Greillier MD, Claire Cropet PhD, Prof Olivier Bylicki MD, Isabelle Monnet MD, Clarisse Audigier-Valette MD, Lionel Falchero MD, Prof Alain Vergnenègre MD, Pierre Demontrond MD, Margaux Geier MD, Prof Florian Guisier MD, Stéphane Hominal MD, Chrystèle Locher MD, Romain Corre MD, Prof Christos Chouaid MD, Charles Ricordel MD, GFPC 08–2015 ENERGY investigators, Hervé LENA, Alain VERGNENEGRE, Chrystèle LOCHER, Margaux GEIER, Thomas PASCAL, Laurent GREILLIER, Pierre FOURNEL, Maurice PEROL, Lionel FALCHERO, Stéphanie MARTINEZ, Nicolas PALEIRON, Florian GUISIER, Gwenaëlle LE GARFF, Hélène DOUBRE, Stéphane HOMINAL, Jean-Bernard AULIAC, Marie WISLEZ, Gonzague DE CHABOT, Pierre-Alexandre HAUSS, Isabelle MONNET, Pascal ASSOULINE, Cécile DUJON, Hervé LE FLOCH, Pierre DEMONTROND, Régine LAMY, Géraldine FRANCOIS, Marie MARCQ, Clarisse AUDIGIER-VALETTE, Anne MADROSZYK-FLANDIN, Jacky CREQUIT, Roland SCHOTT, Samir ABDICHE, Marielle SABATINI, Thierry CHATELLIER, Romain CORRE, Jacques LE TREUT
The Lancet Respiratory Medicine ( IF 38.7 ) Pub Date : 2024-10-29 , DOI: 10.1016/s2213-2600(24)00264-9 Hervé Léna MD, Prof Laurent Greillier MD, Claire Cropet PhD, Prof Olivier Bylicki MD, Isabelle Monnet MD, Clarisse Audigier-Valette MD, Lionel Falchero MD, Prof Alain Vergnenègre MD, Pierre Demontrond MD, Margaux Geier MD, Prof Florian Guisier MD, Stéphane Hominal MD, Chrystèle Locher MD, Romain Corre MD, Prof Christos Chouaid MD, Charles Ricordel MD, GFPC 08–2015 ENERGY investigators, Hervé LENA, Alain VERGNENEGRE, Chrystèle LOCHER, Margaux GEIER, Thomas PASCAL, Laurent GREILLIER, Pierre FOURNEL, Maurice PEROL, Lionel FALCHERO, Stéphanie MARTINEZ, Nicolas PALEIRON, Florian GUISIER, Gwenaëlle LE GARFF, Hélène DOUBRE, Stéphane HOMINAL, Jean-Bernard AULIAC, Marie WISLEZ, Gonzague DE CHABOT, Pierre-Alexandre HAUSS, Isabelle MONNET, Pascal ASSOULINE, Cécile DUJON, Hervé LE FLOCH, Pierre DEMONTROND, Régine LAMY, Géraldine FRANCOIS, Marie MARCQ, Clarisse AUDIGIER-VALETTE, Anne MADROSZYK-FLANDIN, Jacky CREQUIT, Roland SCHOTT, Samir ABDICHE, Marielle SABATINI, Thierry CHATELLIER, Romain CORRE, Jacques LE TREUT
Combined treatment with anti-PD-1 and anti-CTLA-4 antibodies has shown superiority over chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC), but data for older patients (aged ≥70 years) with an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1 or those with an ECOG performance status of 2 are scarce. We aimed to test the superiority of the PD-1 antibody nivolumab and the CTLA-4 antibody ipilimumab over platinum-based doublet chemotherapy as first-line treatment in patients with NSCLC aged 70 years or older or with an ECOG performance status of 2.
中文翻译：
纳武利尤单抗加伊匹木单抗与基于卡铂的双药作为年龄≥ 或 ECOG 体能状态为 2 的晚期非小细胞肺癌患者的一线治疗 （GFPC 08–2015 ENERGY）：一项随机、开放标签的 3 期研究
在晚期非小细胞肺癌 （NSCLC） 患者中，抗 PD-1 和抗 CTLA-4 抗体的联合治疗优于化疗，但东部肿瘤合作组 （ECOG） 体能状态为 0-1 或 ECOG 体能状态为 2 的老年患者（≥70 岁）的数据很少。我们旨在测试 PD-1 抗体纳武利尤单抗和 CTLA-4 抗体 ipilimumab 作为 70 岁或以上或 ECOG 体能状态为 2 的 NSCLC 患者作为一线治疗的铂类双药化疗的优越性。
更新日期：2024-10-29
中文翻译：
纳武利尤单抗加伊匹木单抗与基于卡铂的双药作为年龄≥ 或 ECOG 体能状态为 2 的晚期非小细胞肺癌患者的一线治疗 （GFPC 08–2015 ENERGY）：一项随机、开放标签的 3 期研究
在晚期非小细胞肺癌 （NSCLC） 患者中，抗 PD-1 和抗 CTLA-4 抗体的联合治疗优于化疗，但东部肿瘤合作组 （ECOG） 体能状态为 0-1 或 ECOG 体能状态为 2 的老年患者（≥70 岁）的数据很少。我们旨在测试 PD-1 抗体纳武利尤单抗和 CTLA-4 抗体 ipilimumab 作为 70 岁或以上或 ECOG 体能状态为 2 的 NSCLC 患者作为一线治疗的铂类双药化疗的优越性。
京公网安备 11010802027423号